Wie hoch ist der Preis für Pascal Biosciences Inc. (PSCBF)

Preis für Pascal Biosciences Inc. (PSCBF) ist $0.1

Wie hoch ist die Marktkapitalisierung für Pascal Biosciences Inc. (PSCBF)

Marktkapitalisierung für Pascal Biosciences Inc. (PSCBF) ist $1.31M

Pascal Biosciences Inc. (PSCBF) KBV

Pascal Biosciences Inc. is an innovative biopharmaceutical firm dedicated to discovering and advancing therapeutic solutions for oncology and bolstering immune system function. The company's robust pipeline includes several key candidates: PAS-403, a potent mitosis inhibitor designed to impede cancerous cell division, specifically targeting glioblastoma and secondary brain tumors; and PAS-393, an immunomodulatory cannabinoid developed to enhance the immune system's recognition of tumor cells when utilized alongside checkpoint inhibitor therapy. Furthermore, Pascal is progressing a specialized antibody therapy aimed at B-cells, intended for conditions like acute lymphoblastic leukemia and various B-cell lymphomas. The company is also investigating cannabinoid-derived products as potential treatments for COVID-19. To support its research, Pascal Biosciences maintains an exclusive licensing agreement with the University of Washington for a cannabinoid-based therapeutic against glioblastoma multiforme and brain metastases. It also benefits from a collaborative research partnership with SoRSE Technology Corporation, focused on advancing PAS-393 toward clinical trials. Founded in 2011, the company operates from its headquarters in Seattle, Washington.

Jahr	P/B-Verhältnis	ändert
2026 (TTM)	2.64	127.72%
2023	1.16	-181.08%
2022	-1.43	7,479.37%
2021	-0.02	6,200.00%
2020	0.00	0.00%
2019	0.00	0.00%

Jahr

P/B-Verhältnis

ändert

2026 (TTM)

2.64

127.72%

2023

1.16

-181.08%

2022

-1.43

7,479.37%

2021

-0.02

6,200.00%

2020

0.00

0.00%

2019

0.00

0.00%

Unternehmen	P/B-Verhältnis	P/B-Verhältnis-Differenz	Land
Vertex Pharmaceuticals Incorporated VRTX.US	6.2613	137.04%	US
Argenx SE ARGX.US	6.3483	140.33%	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	3.634	37.57%	BE

Unternehmen

P/B-Verhältnis

P/B-Verhältnis-Differenz

Land